Ensysce Biosciences Announces Successful Completion of Clinical Study for Pain Medication with Overdose Protection, Amgen and TScan Therapeutics Collaborate to Identify Antigens for Crohn's Disease Treatment
- May 09th, 2023
- 388 views
Ensysce Biosciences, Inc. (Nasdaq: ENSC) has completed the clinical study of its first pain medication with overdose protection, PF614-MPAR, known as PF614-MPAR-101. The final Part B of the study showed that PF614-MPAR effectively reduced opioid delivery when three or more doses were consumed simultaneously, with dose escalation from 25 to 200 mg (1 to 8 dose units).
In other news, Amgen (Nasdaq: AMGN) and TScan Therapeutics, Inc. (Nasdaq: TCRX) have announced a collaboration to identify antigens recognized by T cells in Crohn's disease patients. TScan will receive a $30 million upfront payment and may receive over $500 million in success-based preclinical, clinical, regulatory and commercial milestones. Additionally, tiered single-digit royalty payments will be made.
$ENSC is trading at $5.96, up by 73.33% or $2.52. Meanwhile, $TCRX is trading at $4.25, up by 97.67% or $2.10.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Earnings Preview: Walt Disney, Applied Materials, and Celcuity Take Center Stage
November 11th, 2024Key Metrics: CyberArk Software, Hudbay Minerals, and Sonos Earnings Due
November 11th, 2024Earnings: What to Expect from Occidental Petroleum, Rocket Lab, and CAE
November 10th, 2024Earnings Countdown: Home Depot, Sea Limited, and Natera in the Spotlight
November 10th, 2024Ahead of Earnings: DoorDash, MetLife, and Exelon in the Spotlight
October 27th, 2024
Member Login